Supplementary Figure S1 from Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
Year: 2023
Type: supplementary-materials
Abstract: Sunitinib (A) and Regorafenib (B) plasma concentration (ng/mL) across several timepoints during cycle 1.
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361936680